文献速递淋巴瘤

蛋白质组学鉴定凋亡标志物作为滤泡性淋巴瘤组织学转化的预测因子

Proteomics identifies apoptotic markers as predictors of histological transformation in patients with follicular lymphoma.
PubMed 文献 · Blood Adv · 2023-01-01

本研究通过无标记定量纳升液相色谱-串联质谱分析,比较了后续发生组织学转化(st-FL,n=20)与未转化(nt-FL,n=34)的滤泡性淋巴瘤患者诊断时淋巴瘤样本的蛋白表达差异。结果显示st-FL与nt-FL存在差异蛋白表达,涉及凋亡、细胞骨架、细胞周期和免疫过程通路。免疫组化证实凋亡蛋白CASP3、MCL1、BAX、BCL-xL和BCL-rambo在st-FL中表达更高,且与更短的无转化生存期相关。

要点

  • 诊断时st-FL与nt-FL样本存在差异蛋白表达谱,可识别高转化风险患者。
  • 凋亡蛋白CASP3、MCL1、BAX、BCL-xL和BCL-rambo在st-FL中表达高于nt-FL。
  • 5种凋亡标志物均与更短的无转化生存期相关,风险评分随阳性标志物数量增加提示无转化生存期更差。

核心结论

  • 蛋白质组学在滤泡性淋巴瘤诊断时识别出改变的蛋白表达谱(尤其是凋亡蛋白),可预测后续组织学转化。

研究设计与样本

  • 比较诊断时淋巴瘤样本的蛋白质组学研究,采用无标记定量纳升液相色谱-串联质谱分析。
  • 后续发生组织学转化的滤泡性淋巴瘤(st-FL)样本n=20,未发生转化的滤泡性淋巴瘤(nt-FL)样本n=34。
  • 配对比较诊断时st-FL样本与转化后滤泡性淋巴瘤样本(n=20)。

主要发现

  • st-FL与nt-FL诊断样本间存在差异蛋白表达,涉及凋亡、细胞骨架、细胞周期和免疫过程通路。
  • 诊断时st-FL与配对转化后样本比较显示差异蛋白谱和通路紊乱,提示从诊断到转化存在显著生物学差异。
  • 免疫组化显示CASP3在st-FL中表达高于nt-FL(P < .001)。
  • 免疫组化显示MCL1在st-FL中表达高于nt-FL(P = .015)。
  • 免疫组化显示BAX在st-FL中表达高于nt-FL(P = .003),BCL-xL在st-FL中表达高于nt-FL(P = .025),BCL-rambo在st-FL中表达高于nt-FL(P = .057)。

关键数值与推荐

  • CASP3表达与更短无转化生存期相关(P < .001)。
  • MCL1表达与更短无转化生存期相关(P = .002)。
  • BAX表达与更短无转化生存期相关(P < .001)。
  • BCL-xL表达与更短无转化生存期相关(P = .069)。
  • BCL-rambo表达与更短无转化生存期相关(P = .010)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Follicular lymphoma (FL) is an indolent lymphoma with a generally favorable prognosis. However, histological transformation (HT) to a more aggressive disease leads to markedly inferior outcomes. This study aims to identify biological differences predictive of HT at the time of initial FL diagnosis. We show differential protein expression between diagnostic lymphoma samples from patients with subsequent HT (subsequently-transforming FL [st-FL]; n = 20) and patients without HT (nontransforming FL [nt-FL]; n = 34) by label-free quantification nano liquid chromatography-tandem mass spectrometry analysis. Protein profiles identified patients with high risk of HT. This was accompanied by disturbances in cellular pathways influencing apoptosis, the cytoskeleton, cell cycle, and immune processes. Comparisons between diagnostic st-FL samples and paired transformed FL (n = 20) samples demonstrated differential protein profiles and disrupted cellular pathways, indicating striking biological differences from the time of diagnosis up to HT. Immunohistochemical analysis of apoptotic proteins, CASP3, MCL1, BAX, BCL-xL, and BCL-rambo, confirmed higher expression levels in st-FL than in nt-FL samples (P < .001, P = .015, P = .003, P = .025, and P = .057, respectively). Moreover, all 5 markers were associated with shorter transformation-free survival (TFS; P < .001, P = .002, P < .001, P = .069, and P = .010, respectively). Notably, combining the expression of these proteins in a risk score revealed increasingly inferior TFS with an increasing number of positive markers. In conclusion, proteomics identified altered protein expression profiles (particularly apoptotic proteins) at the time of FL diagnosis, which predicted later transformation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Enemark MBH, Wolter K, Campbell AJ, et al. Proteomics identifies apoptotic markers as predictors of histological transformation in patients with follicular lymphoma. Blood Adv. 2023. PMID: 37824846. doi:10.1182/bloodadvances.2023011299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。